- preferences/values
- methods and metrics
- costing methods
- health outcomes
- evidence synthesis
- test performance
- value of information
- models and tools
- mathematical models
- state-transition
- dynamic transmission
- microsimulation
- dynamic simulation
- chronic disease/risk
- health/medicine
- science/technology
- global
- middle east & north africa
- europe
Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Evidence Synthesis | Costing Methods | Health Outcomes | Health/Medicine | Science/Technology | Global | Chronic Disease/Risk | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Economics/Finance | Government/Law -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Costing Methods | Health Outcomes | Health/Medicine | Science/Technology | Middle East & North Africa | Chronic Disease/Risk | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Sub-Saharan Africa | Latin America & Caribbean | Asia & Pacific -
ReportPublication 2017DCP3: Cardiovascular, Respiratory, and Related Disorders
This report from the World Bank is the fifth volume of the Disease Control Priorities, …
This report from the World Bank is the fifth volume of the Disease Control Priorities, Third Edition (DCP3) series. It addresses the disease burden of cardiovascular, respiratory, and related disorders (CVRDs), which account for more than half of global adult deaths, mostly in low- and middle-income countries. While CVRDs are mostly preventable or can be treated to reduce morbidity, such interventions are costly and require greater capacity to detect and treat early. When combined with…
Evidence Synthesis | Costing Methods | Health Outcomes | Health/Medicine | Global | Chronic Disease/Risk | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Global Governance | Climate/Environment -
ReportPublication 2015DCP3: Cancer
This report from the World Bank is the third volume of the Disease Control Priorities, …
This report from the World Bank is the third volume of the Disease Control Priorities, Third Edition (DCP3) series. It presents data on the complex patterns of cancer incidence and deaths globally, and offers evidence on effective measures to control cancers. This report identifies settings in which cancer treatment may be ineffective or wasteful, and offers alternative cancer care packages that are cost-effective and better suited to low-resource environments. The Disease Control Priorities Network (DCP)…
Evidence Synthesis | Costing Methods | Health Outcomes | Health/Medicine | Global | Chronic Disease/Risk | Cost-Effectiveness Analysis | Health Systems | Global Governance | Economics/Finance -
ReviewPublication 2018Primary & Secondary Prevention Interventions for Cardiovascular Disease in LMIC's
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for …
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for the money, the authors conducted a systematic review, including 50 studies. Included studies were those that reported full economic evaluations of individual and population-based interventions (pharmacologic and non-pharmacologic), for primary and secondary prevention of CVD among adults in LMIC. The majority of the studies were of modelled evaluations, with significant heterogeneity in methods. Most of the economic evaluations evaluated were…
Evidence Synthesis | Costing Methods | Health Outcomes | Health/Medicine | Global | Chronic Disease/Risk -
ReviewPublication 2023Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic …
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic drugs (NIADs) within glucagon-like peptide-1 (GLP1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP4) inhibitors for treating type 2 diabetes mellitus (T2DM). The study focused on economic results and underlying methodological choices. Methods included searching PubMed, Embase, and Econlit databases from January 1, 2018, to November 15, 2022. Two reviewers screened titles, abstracts, and full texts for relevance…
Evidence Synthesis | Mathematical Models | Health/Medicine | Europe | Chronic Disease/Risk | Cost-Effectiveness Analysis -
ReviewPublication 2023Economic & Humanistic Burden of Osteoarthritis: Systematic Review of Large Sample Studies
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported …
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported by large sample studies since 2016. Medline (via Ovid) and Embase were searched using an updated strategy based on a previous review. Studies with a sample size ≥1000 that measured direct or indirect costs or health-related quality of life (HRQL) of OA were included. Pairs of reviewers independently screened studies, and an arbitrator resolved discrepancies. The Kappa value for agreement…
Evidence Synthesis | Preferences/Values | Health/Medicine | Global | Chronic Disease/Risk | Cost-Effectiveness Analysis -
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Preferences/Values | Health Outcomes | Health/Medicine | Europe | Chronic Disease/Risk | Decision Analysis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | North America -
ReportPublication 2015Chapter 4: Cervical Cancer
This chapter focuses on the possibility of primary prevention of cervical cancer as a result …
This chapter focuses on the possibility of primary prevention of cervical cancer as a result of the introduction of two commercially available vaccines against human papillomavirus (HPV). Few low- and middle-income countries (LMICs) have initiated or sustained cytology-based cervical cancer prevention programs, and these countries experience very high incidence and mortality rates. Fortunately, alternative strategies to prevent cervical cancer have been investigated and extensively evaluated in these settings. The authors report findings from cost-effectiveness analyses…
Mathematical Models | Health/Medicine | Science/Technology | Global | Chronic Disease/Risk | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Clinical Care